Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...

Gilead Sciences (Nasdaq: GILD) reported flat revenues for the first quarter of 2025, with total sales reaching $6.7 billion, ...

Gilead Sciences and Sophia Forum, a London-based charity, have launched a campaign to improve HIV care and outreach for women ...

Key Takeaways Gilead Sciences missed first-quarter revenue estimates as sales of its COVID-19 and cancer drugs declined.The ...

Gilead Sciences on Thursday reported $6.7 billion ... demand for a decline in cancer cell therapy revenue. Gilead’s HIV drug business, though, helped offset those losses, garnering $4.6 billion ...

Women are being overlooked in the UK's HIV response and can face barriers to accessing prevention, testing, and care, ...

Gilead’s HIV product sales, which make up the bulk of its revenue, increased 6% YoY to $4.6 billion, but fell 16% ...

Gilead Sciences offers steady dividend growth with a 2.99% yield. Read why the analyst nonetheless has a neutral rating on ...

By Deena Beasley (Reuters) -Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver disease, along with expense tightening ...